AdaptHealth's (AHCO) Sell (D+) Rating Reaffirmed at Weiss Ratings

Key Points

• Weiss Ratings has reaffirmed a "sell (D+)" rating for AdaptHealth (NASDAQ: AHCO), indicating ongoing concerns about the company's stock performance.
• Recent analyses have shown a mix of ratings for AdaptHealth, including a downgrade from Zacks Research to a "strong sell" and an upgrade by Wall Street Zen to "strong buy," highlighting volatility in analyst opinions.
• The stock price of AdaptHealth has shown some fluctuation, trading at approximately $9.39, with an average consensus price target set at $13.40.

AdaptHealth (NASDAQ:AHCO - Get Free Report)'s stock had its "sell (d+)" rating restated by research analysts at Weiss Ratings in a note issued to investors on Friday,Weiss Ratings reports.

Several other equities analysts have also weighed in on AHCO. Zacks Research lowered shares of AdaptHealth from a "hold" rating to a "strong sell" rating in a research report on Friday, September 19th. Wall Street Zen raised shares of AdaptHealth from a "buy" rating to a "strong-buy" rating in a research report on Sunday, October 19th. Five analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. According to data from MarketBeat, AdaptHealth currently has an average rating of "Hold" and a consensus price target of $13.40.

AdaptHealth Stock Up 1.7%

AHCO traded up $0.16 during midday trading on Friday, hitting $9.39. 120,709 shares of the company's stock traded hands, compared to its average volume of 1,314,741. The company has a market cap of $1.27 billion, a PE ratio of 17.38, a price-to-earnings-growth ratio of 1.16 and a beta of 1.61. The stock's fifty day simple moving average is $9.17 and its 200-day simple moving average is $9.00. The company has a debt-to-equity ratio of 1.14, a current ratio of 1.06 and a quick ratio of 0.82. AdaptHealth has a one year low of $7.11 and a one year high of $11.63.

Insider Buying and Selling

In other AdaptHealth news, Director David Solomon Williams III sold 8,200 shares of the stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $9.73, for a total transaction of $79,786.00. Following the transaction, the director owned 50,045 shares in the company, valued at $486,937.85. This trade represents a 14.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 1.55% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On AdaptHealth

Several hedge funds and other institutional investors have recently modified their holdings of the stock. CWM LLC grew its stake in shares of AdaptHealth by 17.5% in the third quarter. CWM LLC now owns 12,306 shares of the company's stock worth $110,000 after acquiring an additional 1,835 shares during the last quarter. Exchange Traded Concepts LLC bought a new position in shares of AdaptHealth during the third quarter valued at $1,171,000. GAMMA Investing LLC lifted its holdings in shares of AdaptHealth by 31.0% during the third quarter. GAMMA Investing LLC now owns 13,583 shares of the company's stock valued at $122,000 after acquiring an additional 3,218 shares during the period. State of Wyoming raised its holdings in shares of AdaptHealth by 34.6% in the second quarter. State of Wyoming now owns 59,171 shares of the company's stock valued at $558,000 after buying an additional 15,205 shares during the last quarter. Finally, Public Sector Pension Investment Board raised its holdings in shares of AdaptHealth by 6.8% in the second quarter. Public Sector Pension Investment Board now owns 359,744 shares of the company's stock valued at $3,392,000 after buying an additional 22,868 shares during the last quarter. Institutional investors and hedge funds own 82.67% of the company's stock.

AdaptHealth Company Profile

AdaptHealth Corp., together with its subsidiaries, sells home medical equipment (HME), medical supplies, and home and related services in the United States. The company provides sleep therapy equipment, supplies, and related services, such as CPAP and bi-PAP services to individuals suffering from obstructive sleep apnea; medical devices and supplies, including continuous glucose monitors and insulin pumps for the treatment of diabetes; HME to patients discharged from acute care and other facilities; oxygen and related chronic therapy services in the home; and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy, and nutritional supply needs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.